A lack of rapid, accessible, scalable, and accurate biochemical methods to quantify amylin-Aβ interaction prevents larger sample studies, hindering the development of therapeutic strategies to prevent brain amylin accumulation and interaction with AD pathology. This evidence concerns the gene IAPP and Alzheimer disease.